Plant Name: Uncaria africana
Taxonomic Information:
Plant ID: NPO23478
Plant Latin Name: Uncaria africana
Taxonomy Genus: Uncaria
Taxonomy Family: Rubiaceae
Plant External Links:
NCBI TaxonomyDB:
170182
Plant-of-the-World-Online:
768207-1
Used in Medicines:
Country/Region:
Kenya; Tanzania; Rwanda; ChinaTraditional Medicine System:
TCMGeographical Distribution:
Madagascar; Sudan; Guinea; Ethiopia; Rwanda; Nigeria; Cameroon; Cote d'Ivoire; Ghana; Burkina Faso; Togo; China; Sierra Leone; Liberia; Tanzania; Gabon; Guinea-Bissau; Angola; Equatorial Guinea; Senegal; Congo; Uganda; Kenya; Comoros
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRA2C; ADRA2A; ADRA2B; | |
| CA2; CA7; CA4; CA14; | |
| PPARA; | |
| ALOX15; CBR1; | |
| XDH; | |
| LMNA; FABP5; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.300E-12 | 1.415E-08 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2D6, XDH |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.998E-12 | 1.679E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.728E-11 | 5.376E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.398E-10 | 2.768E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 8.068E-10 | 1.171E-06 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 9.062E-10 | 1.233E-06 | CA14, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.902E-09 | 2.437E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2D6 |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 3.225E-09 | 3.512E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 3.225E-09 | 3.512E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.959E-09 | 4.105E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.611E-08 | 1.253E-05 | CYP1A2, CYP2C19, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 3.043E-08 | 2.285E-05 | CYP19A1, CYP1A1, CYP2C19, CYP2D6 |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 4.504E-08 | 3.164E-05 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 4.504E-08 | 3.164E-05 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.851E-08 | 5.354E-05 | CA14, CA2, CA4, CA7 |
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 9.101E-07 | 3.964E-04 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.411E-06 | 5.910E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.748E-06 | 1.050E-03 | CA2, CA7 |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 4.736E-06 | 1.719E-03 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 5.494E-06 | 1.929E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.644E-06 | 1.951E-03 | CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.919E-05 | 5.499E-03 | CYP1A2, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 1.919E-05 | 5.499E-03 | CYP1A1, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 2.558E-05 | 7.050E-03 | CYP1A1, CYP1A2 |
| BP | Unclassified; | GO:0019229; regulation of vasoconstriction | 2.665E-05 | 7.254E-03 | ADRA2A, ADRA2B, ADRA2C |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 6.298E-09 | 1.102E-07 | CBR1, CYP2D6, CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.373E-09 | 4.807E-08 | CA2, CA4, CA7, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.138E-08 | 1.328E-07 | CBR1, CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.389E-07 | 2.090E-06 | CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 7.024E-06 | 4.097E-05 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.385E-05 | 6.059E-05 | CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.615E-06 | 1.830E-05 | CYP1A2, ALOX15, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 2.653E-05 | 1.032E-04 | CBR1, ALOX15, CYP2C19 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 8.960E-05 | 2.851E-04 | CBR1, CYP1A2, ALOX15, CYP1A1, CYP2C19, CYP19A1, XDH |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 3.660E-05 | 1.281E-04 | CYP2D6, CYP1A2, CYP2C19 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.552E-04 | 4.526E-04 | CYP2D6, ALOX15, CYP2C19 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 5.022E-04 | 1.255E-03 | ADRA2C, ADRA2B, ADRA2A |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 2.161E-03 | 4.449E-03 | ADRA2C, ADRA2B, ADRA2A |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.716E-03 | 4.004E-03 | CYP1A2, CYP1A1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 1.931E-03 | 4.225E-03 | FABP5, PPARA |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 2.138E-04 | 5.755E-04 | CA2, CA4 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 8.536E-06 | 4.268E-05 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C; XDH; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C; |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | CBR1; ADRA2C; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2A; ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
